The estimated Net Worth of Barbara White is at least $12.5 Миллион dollars as of 17 March 2020. Barbara White owns over 15,606 units of Corbus Pharmaceuticals Inc stock worth over $10,869,698 and over the last 10 years he sold CRBP stock worth over $0. In addition, he makes $1,672,000 as Chief Medical Officer at Corbus Pharmaceuticals Inc.
Barbara has made over 31 trades of the Corbus Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 15,606 units of CRBP stock worth $56,650 on 17 March 2020.
The largest trade he's ever made was buying 38,000 units of Corbus Pharmaceuticals Inc stock on 17 August 2016 worth over $119,700. On average, Barbara trades about 6,377 units every 50 days since 2014. As of 17 March 2020 he still owns at least 206,217 units of Corbus Pharmaceuticals Inc stock.
You can see the complete history of Barbara White stock trades at the bottom of the page.
Dr. Barbara White M.D. serves as Chief Medical Officer of the Company. Dr. White has served as our Chief Medical Officer since August 2014. Previously, Dr. White served as Senior Vice President and Head of Research and Development at Stiefel, a dermatological pharmaceutical division of GlaxoSmithKline, a public pharmaceutical company, from 2011 to 2013. From 2010 to 2011, Dr. White was Vice President and Head of Immunology Therapeutic Area at UCB, a public biopharmaceutical manufacturing company. At MedImmune, LLC, a subsidiary of AstraZeneca plc, a public pharmaceutical company, Dr. White served first as Senior Director of Clinical Development from 2006 until 2007, and then as Vice President until 2010. Prior to her pharmaceutical career, Dr. White was Professor and Associate Chair of Research, Department of Medicine, at the University of Maryland School of Medicine. She was formerly Associate Chief of Staff, Research Service, at the Baltimore Veteran Administration (VA) Medical Center, where her research focused on immune-mediated mechanisms of lung fibrosis in scleroderma. Barbara also previously served as Co-Director of the Johns Hopkins University and University of Maryland Scleroderma Center. Barbara received her medical degree from the University of Pennsylvania School of Medicine and is board certified in internal medicine, rheumatology and allergy/clinical immunology. She completed her postdoctoral studies in basic cellular immunology at the National Institutes of Health.
As the Chief Medical Officer of Corbus Pharmaceuticals Inc, the total compensation of Barbara White at Corbus Pharmaceuticals Inc is $1,672,000. There are 1 executives at Corbus Pharmaceuticals Inc getting paid more, with Yuval Cohen having the highest compensation of $4,001,510.
Barbara White is 69, he's been the Chief Medical Officer of Corbus Pharmaceuticals Inc since 2014. There are 2 older and 9 younger executives at Corbus Pharmaceuticals Inc. The oldest executive at Corbus Pharmaceuticals Holdings Inc is Avery Catlin, 72, who is the Independent Director.
Barbara's mailing address filed with the SEC is C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062.
Over the last 10 years, insiders at Corbus Pharmaceuticals Inc have traded over $3,643,182 worth of Corbus Pharmaceuticals Inc stock and bought 2,676,074 units worth $50,292,165 . The most active insiders traders include Asset Management, Lp Chen B..., Asset Management, Lp Cormor... и Sean F. Moran. On average, Corbus Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of $1,059,576. The most recent stock trade was executed by Sean F. Moran on 14 June 2024, trading 18,043 units of CRBP stock currently worth $233,837.
corbus pharmaceuticals holdings, inc. (nasdaq: crbp) is a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases with clear unmet needs. the company's lead product candidate, resunab™, is a first-in-class, oral anti-inflammatory drug that acts to resolve inflammation through an endogenous pathway. resunab is scheduled to commence three phase 2 clinical trials in 2015 for the treatment of cystic fibrosis, diffuse systemic sclerosis ("scleroderma") and dermatomyositis, three diseases in which inflammation contributes to disease progression. resunab also has the potential to treat additional rare, inflammatory diseases.
Corbus Pharmaceuticals Inc executives and other stock owners filed with the SEC include: